PDEs as modifiers of the IGFR pathways and methods of use
AssigneeExelixis, Inc.
InventorsLori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Lynn Margaret Bjerke, Timothy S. Heuer
Life of this patent
Estimating the term…
Abstract
Human PDE genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of PDE are provided.
Claims22
A method of identifying a candidate IGFR pathway modulating agent, said method comprising the steps of:
- (a) providing an assay system comprising a PDE polypeptide or nucleic acid;
- (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity;
- and
- (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate IGFR pathway modulating agent.
A method for modulating a IGFR pathway of a cell comprising contacting a cell defective in IGFR function with a candidate modulator that specifically binds to a PDE polypeptide, whereby IGFR function is restored.
A method of modulating IGFR pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a PDE polypeptide or nucleic acid.
Dependencies are inferred from the claim text.